Management ChangeMay 8, 2026, 05:16 PM
Nektar Therapeutics Appoints Linda Rubinstein as Interim CFO
AI Summary
Sandra Gardiner will retire as Nektar Therapeutics' interim Chief Financial Officer on May 15, 2026, after serving since April 2023. Linda Rubinstein, a partner at FLG Partners, LLC, will succeed her, bringing over 35 years of operational, financial, and capital markets experience in life sciences. Separately, Nektar entered an Equity Distribution Agreement to potentially offer and sell up to $150,000,000 of common stock through an "at-the-market" offering, paying a 3.0% commission on sales.
Key Highlights
- Interim CFO Sandra Gardiner to retire effective May 15, 2026.
- Linda Rubinstein appointed interim CFO, effective May 15, 2026.
- Ms. Rubinstein brings over 35 years of experience in life sciences and investment banking.
- FLG will be paid $650 per hour for Ms. Rubinstein's services.
- Nektar entered an Equity Distribution Agreement for an at-the-market (ATM) offering.
- Company may sell up to $150,000,000 in common stock through sales agents.
- Nektar will pay a 3.0% commission on the gross sales price of shares sold.